Alkermes plc (ALKS) Guidance & Earnings Results

On 2026-07-28 Alkermes plc reaffirmed guidance: "Revenue guidance unchanged $1,730-$1,840M; GAAP net loss widened to ($95)-($115)M; adjusted EBITDA unchanged…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

ALKSAlkermes plcFollow ALKS — free

Drug Manufacturers - Specialty & Generic · Healthcare

—

Price chart with a free account

Market cap: 7.3B
P/E TTM: 114.8
Dividend yield: —
52-week: —
Next earnings: 3 Nov, in 10 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
28 Jul 26	Reaffirmed	Revenue guidance unchanged $1,730-$1,840M; GAAP net loss widened to ($95)-($115)M; adjusted EBITDA unchanged $370-$410M · full year
5 May 26	Reaffirmed	Updated non-cash elements of 2026 full year financial expectations, improving GAAP net loss and EBITDA · full year
25 Feb 26	Reaffirmed	FY2026 financial expectations provided; expects robust cash generation and profitability. · full year
28 Oct 25	Raised	Total Revenues raised to $1.43B-$1.49B from $1.34B-$1.43B; GAAP Net Income raised to $230M-$250M from $175M-$205M · full year
29 Jul 25	—	Revenues $10.0-10.25B (BHC consolidated), $4.95-5.1B (BHC excl B+L), $5.05-5.15B (B+L); Adj EBITDA $3.485-3.635B (BHC consolidated), $2.625-2.725B (BHC excl B+L), $0.86-0.91B (B+L); Adj Cash Flow from Ops $0.825-0.875B (BHC excl B+L). · full year

Alkermes plc — questions

What guidance did Alkermes plc give?: On 2026-07-28: "Revenue guidance unchanged $1,730-$1,840M; GAAP net loss widened to ($95)-($115)M; adjusted EBITDA unchanged $370-$410M"
When does Alkermes plc report earnings?: Alkermes plc's next earnings report is expected on 2026-11-03.

Every figure on this page comes from Alkermes plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.